<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210307050610N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-05-11</date_registration>
      <primary_sponsor>Sabzevar University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of serum replacement frequency used in drug infusion on serum contamination and incidence of phlebitis</public_title>
      <acronym>ندارد</acronym>
      <scientific_title>Investigation the effect of the 24  and 48-hour changing in chloride sodium  0.9% used in infusion of drug on the amount of phlebitis and serum infection</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>300</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54842</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Other design features: not, Randomization description: By simple random sampling method of people referring to Hashemi Rafsanjani Hospital in Shirvan who are eligible after sample selection is divided into two experimental groups (with 48-hour change of 0.9% sodium chloride serum) and the control group (with normal 24-hour change) be. In this study, individuals were assigned to two groups using permutation block method. In this method, A represents the individual receiving the intervention and B represents the individual in the control group. Considering the quadruple block; Instead of AABB code 0, give ABAB code 1, ABBA code 2, BAAB code 3, BBAA code 4 and BABA code 5. Then, using a table of random numbers, he randomly selected the starting point. Considering the order of the numbers in the table, we place the permutation corresponding to each number we encounter. So finally, by selecting the numbers from the table, how to assign a total of 300 people to the two groups will be determined, Blinding description: The data analyzer does not know which group the people are in.
Laboratory samples are given to the laboratory expert anonymously based on numbers and he does not know if the samples are in the intervention or control group.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Phlebitis. Condition 2: Catheter-related infection.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The serum used in the infusion of drugs will be changed every 48 hours. At the end of 48 hours from the start of serum infusion, 5 cc of each serum was drawn with a syringe and sterile method and sent to the laboratory under sterile conditions and in the shortest possible time and each sample was cultured by a blind laboratory expert. Then count the number of colonies that appear and if more than fifteen microbial growths are seen in each container, the result of positive culture and the corresponding serum will be considered infected. If the number of colonies was less than or equal to 15 and the person was asymptomatic, serum is considered colonization. Intervention 2: Control group: The serum control group used in the infusion of drugs will be changed every 24 hours. At the end of 48 hours from the start of serum infusion, 5 cc of each serum was drawn with a syringe and sterile method and sent to the laboratory under sterile conditions and in the shortest possible time and each sample was cultured by a blind laboratory expert. Then count the number of colonies that appear and if more than fifteen microbial growths are seen in each container, the result of positive culture and the corresponding serum will be considered infected. If the number of colonies was less than or equal to 15 and the person was asymptomatic, serum is considered colonization.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "No more information"</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hasan Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Campus of University of Medical Sciences,Nuclear Martyrs Blvd</address>
        <city>Sabzvar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9617913112</zip>
        <telephone>+98 51 4408 6458</telephone>
        <email>khaalili894@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hasan Khalili</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Vice Chancellor for Education, University, Tohid Shahr Blvd</address>
        <city>sabzvar</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9613873136</zip>
        <telephone>+98 51 4401 1300</telephone>
        <email>khalili894@gmail.com</email>
        <affiliation>Sabzevar University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People over the age of 18
patient consent or caregiver
patient cooperation
having a drug to be infused
patients who have been hospitalized for at least 48 hours</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant patients
lactating patients
immunocompromised patients
Patients with skin and vascular diseases
Patients receiving hypertonic serum
and patients receiving blood and blood products
patients receivingTotal parenteral nutrition
Patients with sepsis
patients with mental disorders
Patients receiving anticoagulants
If you have a local infection at the catheter injection site</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T81.7</hc_code>
      <hc_code>T85.7</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Vascular complications following a procedure, not elsewhere classified</hc_keyword>
      <hc_keyword>Infection and inflammatory reaction due to other internal prosthetic devices, implants and grafts</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The serum used in the infusion of drugs will be changed every 48 hours. At the end of 48 hours from the start of serum infusion, 5 cc of each serum was drawn with a syringe and sterile method and sent to the laboratory under sterile conditions and in the shortest possible time and each sample was cultured by a blind laboratory expert. Then count the number of colonies that appear and if more than fifteen microbial growths are seen in each container, the result of positive culture and the corresponding serum will be considered infected. If the number of colonies was less than or equal to 15 and the person was asymptomatic, serum is considered colonization.</i_keyword>
      <i_keyword>Control group: The serum control group used in the infusion of drugs will be changed every 24 hours. At the end of 48 hours from the start of serum infusion, 5 cc of each serum was drawn with a syringe and sterile method and sent to the laboratory under sterile conditions and in the shortest possible time and each sample was cultured by a blind laboratory expert. Then count the number of colonies that appear and if more than fifteen microbial growths are seen in each container, the result of positive culture and the corresponding serum will be considered infected. If the number of colonies was less than or equal to 15 and the person was asymptomatic, serum is considered colonization.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Number of phlebitis according to Jackson criteria. Timepoint: During the period of hospitalization. Method of measurement: Jackson criteria.</prim_outcome>
      <prim_outcome>Number of cases of serum contamination. Timepoint: 24 hours in the control group and 48 hours in the experimental group. Method of measurement: Response of serum culture sample sent to laboratory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Number of catheter contamination cases. Timepoint: Discharge of the patient or 72 hours after catheter placement or catheter phlebitis. Method of measurement: Response of the catheter sample sent to the laboratory.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sabzevar University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-06</approval_date>
        <contact_name>Ethics Committee of Sabzevar University of Medical Sciences</contact_name>
        <contact_address>Asadabadi sabzvar Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
